BLOG

BLOG

2023-05-31

News Update Immorna Announces First Subject Dosed in a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Vaccine Developed for the Prevention of Shingles

MORRISVILLE, N.C., May 30, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the first subject has been dosed in the Company's First-In-Human (FIH) Phase 1 multi-center study of JCXH-105, a self-replicating RNA (srRNA) vaccine being developed for the prevention of Shingles (Herpes Zoster; HZ). JCXH-105 represents Immorna's first investigational vaccine targeting infection caused by a latent virus.
More +

2023-01-09

News Update Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine

MORRISVILLE, N.C., January 9, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to conduct a Phase 1 multi-center study of JCXH-105, a self-replicating RNA (srRNA) vaccine against Shingles (Herpes Zoster). JCXH-105 represents Immorna’s first investigational vaccine targeting chronic infection caused by a latent virus.
More +

2022-11-19

News Update Immorna Receives IND Clearance to Conduct a Phase 1/2 Study of JCXH-221, a Broadly Protective mRNA-Based COVID-19 Vaccine

MORRISVILLE, N.C., November 21st, 2022 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to conduct a Phase 1/2 multi-center study of JCXH-221, a lipid nanoparticle (LNP) complexed broadly protective mRNA vaccine against SARS-CoV-2 infection and diseases. The goal of this multi-center study is to assess the safety and immunogenicity of JCXH-221 in healthy adult subjects.
More +

2022-11-07

News Update First Patient Dosed in Phase 1 FIH Study of JCXH-211, the First-in-Class Self-Replicating RNA encoding human IL-12, in Patients with Malignant Solid Tumors

Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the first patient has been dosed at The University of Texas MD Anderson Cancer Center in the Phase 1 First-in-Human (FIH) trial of JCXH-211 in patients with malignant solid tumors. JCXH-211 is a novel, first-in-class, lipid nanoparticle (LNP) encapsulated self-replicating RNA (srRNA) encoding human interleukin (IL)-12 protein.
More +

2022-03-08

Immorna Receives IND Clearance to Conduct FIH Study of JCXH-211, the First-in-Class Self-replicating mRNA

RALEIGH, N.C., March 28, 2022  /PRNewswire/ -- Immorna, a rapidly-expanding biotechnology company developing both self-replicating and conventional mRNA-based therapeutics and vaccines, announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for JCXH-211, a novel self-replicating mRNA encoding human interleukin (IL)-12 protein.
More +

2022-01-31

Immorna Expands Its R&D Footprint in RTP, NC and Appoints Key Senior Scientific Leaders

RALEIGH, N.C., Jan. 31, 2022 /PRNewswire/ -- Immorna, an immune-oncology drug and viral vaccine development company with both proprietary self-replicating mRNA and conventional (non-replicating) mRNA technologies expands its R&D footprint in the US. Today, Immorna announces appointment of Drs. NgocDiep Le, Jeffrey Ulmer, Marcin Bugno, Lan Feng, and Mr. Jeffrey Carey to key roles, strengthening its exiting strong leadership team.
More +
< 123 >

Business license

Statement

SEO